Related Experiment Video
Updated: Jul 23, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
HER-2-Positive Tumors: A Continuously Evolving Field in Cancer Research
Ralf Hofheinz1, Sylvie Lorenzen2, Michael K Bohlmann3
1Mannheim Cancer Center, University Hospital Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Abstract:
Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in the United States of America (USA) [...].
Insights
Trastuzumab, a targeted therapy for HER2-positive breast cancer, has been available for nearly 25 years. This therapy has significantly impacted treatment for patients with metastatic disease.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Trastuzumab, a monoclonal antibody, targets human epidermal growth factor receptor 2 (HER2).
- It was approved in the USA nearly 25 years ago for metastatic HER2-positive breast cancer.
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...

